Pacific Biosciences of California PACB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 28.6%+4.4pp | 24.2%-2.1pp | 26.3%-18.1pp | 44.4%-6.0pp | |
| Operating margin | -346.2%-38.2pp | -308%-141pp | -166.8%+72.6pp | -239.4%-78.2pp | |
| Net margin | -341.5%-139pp | -202.7%-49.8pp | -153%+92.0pp | -244.9%-106pp | |
| EBITDA margin | -107.1%+174pp | -281.2%-124pp | -157%+74.4pp | -231.3%-75.9pp | |
| Free cash flow margin | -71.2%+66.6pp | -137.8%-4.1pp | -133.7%+84.5pp | -218.2%-128pp | |
| Returns | |||||
| Return on equity | -213.5%-162pp | -51.7%-3.2pp | -48.5%-2.1pp | -46.4%-14.2pp | |
| Return on assets | -53.4%-32.7pp | -20.8%-3.3pp | -17.5%-0.8pp | -16.7%-1.7pp | |
| Efficiency | |||||
| Asset turnover | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Inventory turnover | 1.4×-0.3× | 1.7×-1.1× | 2.8×+0.9× | 1.9×-1.4× | |
| Liquidity | |||||
| Current ratio | 5.1×-2.3× | 7.5×-0.3× | 7.8×+4.6× | 3.2×-12.1× | |
| Quick ratio | 4×-2.2× | 6.2×-1.0× | 7.2×+4.2× | 3×-12.0× | |
| Cash ratio | 0.9×0.0× | 0.9×-1.1× | 1.9×+0.7× | 1.2×-5.2× | |
| Leverage | |||||
| Debt-to-equity | 10.7×+10.6× | 0×0.0× | 0.1×-1.6× | 1.7×+0.5× | |
| Debt-to-assets | 0.1×+0.1× | 0×0.0× | 0×-0.5× | 0.5×+0.1× | |
| Interest coverage | -79.6×-44.3× | -35.4×-12.0× | -23.3×-2.4× | -20.9×-4.1× | |
| Per Share | |||||
| Book value per share | $0.02-99.0% | $1.76-36.5% | $2.77+10.3% | $2.51-35.3% | |
| Valuation | |||||
| Market capitalization | $496.96M+30.4% | $538.6M-79.4% | $2.62B+41.6% | $1.85B-58.9% | |
| Enterprise value | $498.38M+33.5% | $505.94M-79.6% | $2.48B+0.4% | $2.47B-50.5% | |
| Price / sales | 3.1×+0.6× | 3.5×-9.6× | 13.1×-1.4× | 14.4×-20.1× | |
| Price / book | 210×+206× | 1.1×-2.7× | 3.7×+0.4× | 3.3×-2.4× | |
| EV / sales | 3.1×+0.7× | 3.3×-9.1× | 12.4×-6.9× | 19.3×-19.0× | |
| Free cash flow yield | -23.4%+23.4pp | -39.4%-29.2pp | -10.2%+4.9pp | -15.1%-12.5pp | |
| Earnings yield | -25.9%+147pp | -58%-46.3pp | -11.7%+5.3pp | -17%-13.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacific Biosciences of California's profit margins?
- Pacific Biosciences of California (PACB) runs a 37.5% gross margin and a -83.3% operating margin, with a -80.3% net margin.
- Where do Pacific Biosciences of California's ratios come from?
- Every ratio is computed from Pacific Biosciences of California's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
